Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

RBIOPHARM FRANCE HOLDING : revenue, balance sheet and financial ratios

RBIOPHARM FRANCE HOLDING is a French company founded 30 years ago, specialized in the sector Fonds de placement et entités financières similaires. Based in SAINT-DIDIER-AU-MONT-D'OR (69370), this company of category PME shows in 2017 a revenue of 7.0 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - RBIOPHARM FRANCE HOLDING (SIREN 403235344)
Indicator 2024 2023 2022 2021 2020 2019 2017 2016 2015
Revenue N/C N/C N/C N/C N/C N/C 7 004 235 € N/C N/C
Net income 1 231 529 € 1 489 588 € 1 889 085 € 992 591 € -7 730 € 993 037 € 334 284 € 1 083 886 € 1 932 264 €
EBITDA N/C -8 732 € -8 077 € -7 409 € -7 730 € -6 963 € 648 476 € -11 034 € -10 325 €
Net margin N/C N/C N/C N/C N/C N/C 4.8% N/C N/C

Revenue and income statement

In 2024, RBIOPHARM FRANCE HOLDING generates positive net income of 1.2 M€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2015-2024: 1.9 M€ -> 1.2 M€.

EBIT (2024) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

-10 297 €

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

1 231 529 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 99%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.0 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

0.431%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

98.821%

Repayment capacity (2024) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

0.004

Solvency indicators evolution
RBIOPHARM FRANCE HOLDING

Sector positioning

Debt ratio
0.43 2024
2022
2023
2024
Q1: 0.01
Med: 13.69
Q3: 116.56
Good

In 2024, the debt ratio of RBIOPHARM FRANCE HOLDING (0.43) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
98.82% 2024
2022
2023
2024
Q1: 13.95%
Med: 55.8%
Q3: 90.35%
Excellent

In 2024, the financial autonomy of RBIOPHARM FRANCE HOLDING (98.8%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.

Repayment capacity
0.0 years 2024
2022
2023
2024
Q1: 0.0 years
Med: 0.15 years
Q3: 4.69 years
Good

In 2024, the repayment capacity of RBIOPHARM FRANCE HOLDING (0.00) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 1202.78. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

1202.778

Liquidity indicators evolution
RBIOPHARM FRANCE HOLDING

Sector positioning

Liquidity ratio
1202.78 2024
2022
2023
2024
Q1: 132.35
Med: 897.73
Q3: 5412.13
Good -19 pts over 3 years

In 2024, the liquidity ratio of RBIOPHARM FRANCE HOLDING (1202.78) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.

Interest coverage
0.0x 2023
2022
2023
Q1: -106.29x
Med: -3.78x
Q3: 0.0x
Excellent

In 2023, the interest coverage of RBIOPHARM FRANCE HOLDING (0.0x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
RBIOPHARM FRANCE HOLDING

Positioning of RBIOPHARM FRANCE HOLDING in its sector

Comparison with sector Fonds de placement et entités financières similaires

Valuation estimate

Indicative estimate only : the number of comparable transactions in this sector is limited (26 transactions). This range of 3 458 962€ to 23 865 299€ is provided for information purposes only and requires in-depth analysis to be confirmed.

Estimated enterprise value 2024
Indicative
3458k€ 15982k€ 23865k€
15 982 467 € Range: 3 458 962€ - 23 865 299€
NAF 5 année 2024

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 26 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Fonds de placement et entités financières similaires)

Compare RBIOPHARM FRANCE HOLDING with other companies in the same sector:

Voir toutes les statistiques du secteur Fonds de placement et entités financières similaires

Frequently asked questions about RBIOPHARM FRANCE HOLDING

What is the revenue of RBIOPHARM FRANCE HOLDING ?

The revenue of RBIOPHARM FRANCE HOLDING in 2017 is 7.0 M€.

Is RBIOPHARM FRANCE HOLDING profitable?

Yes, RBIOPHARM FRANCE HOLDING generated a net profit of 1.2 M€ in 2024.

Where is the headquarters of RBIOPHARM FRANCE HOLDING ?

The headquarters of RBIOPHARM FRANCE HOLDING is located in SAINT-DIDIER-AU-MONT-D'OR (69370), in the department Rhone.

Where to find the tax return of RBIOPHARM FRANCE HOLDING ?

The tax return of RBIOPHARM FRANCE HOLDING is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does RBIOPHARM FRANCE HOLDING operate?

RBIOPHARM FRANCE HOLDING operates in the sector Fonds de placement et entités financières similaires (NAF code 64.30Z). See the 'Sector positioning' section above to compare the company with its competitors.